All In Biotech

Drug Trial Radar · NCT04188548

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 379 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

379

Actual

Start

Dec 10, 2019

Primary completion

Jun 29, 2020

Study completion Dec 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

Conditions

  • Breast Cancer
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Endometrial Cancer

Interventions

  • LY3484356Drug

    Administered orally

  • AbemaciclibDrug

    Administered orally

  • EverolimusDrug

    Administered orally

  • AlpelisibDrug

    Administered orally

  • TrastuzumabDrug

    Administered intravenously

  • Aromatase Inhibitor (AI)Drug

    Anastrozole or Exemestane or Letrozole administered orally (physician choice)

  • PertuzumabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent ToxicitiesTime frame: Baseline through Cycle 1 (21/28 Day Cycle)

Locations

74 sites in 8 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona

  • Highlands Oncology Group

    Springdale, Arkansas

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • University of California, Irvine

    Orange, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Lake Nona DDU

    Orlando, Florida

  • Winship Cancer Center Emory University

    Atlanta, Georgia

  • Community Cancer Center North

    Indianapolis, Indiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Minnesota Oncology/Hematology PA

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Memorial Sloan Kettering - Bergen

    Montvale, New Jersey

  • Memorial Sloan Kettering Cancer Center

    Commack, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Wilmot Cancer Institute

    Rochester, New York

  • Duke University

    Durham, North Carolina

  • Ohio State University Medical Center

    Columbus, Ohio

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Asante Rogue Regional Medical Center

    Medford, Oregon

  • UPMC Hillman Cancer Center Harrisburg

    Harrisburg, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Vanderbilt Health One Hundred Oaks

    Nashville, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Tennessee Oncology Nashville

    Nashville, Tennessee

  • UT Southwestern Med Center

    Dallas, Texas

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas

  • Minnesota Oncology/Hematology PA

    The Woodlands, Texas

  • Oncology and Hematology Associates of Southwest Virginia Inc

    The Woodlands, Texas

  • Texas Oncology - San Antonio Medical Center

    The Woodlands, Texas

  • US Oncology

    The Woodlands, Texas

  • USO-Rocky Mountain Cancer Center

    The Woodlands, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • The University of Vermont Medical Center Inc.

    Burlington, Vermont

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.